Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha/beta T-cell and CD19 B-cell depleted allogeneic stem cell transplantation followed by innate donor lymphocyte infusion for high-risk or relapsed acute leukemia/MDS
NL-OMON34123Phase 2Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Dec 2010
- Modality
- Small Molecules, Peptides, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of innate donor lymphocyte infusion, cyclosporine and zoledronic acid in Acute Leukaemia and myelodysplastic syndrome (MDS), sponsored by University Medical Center Utrecht. Primary endpoints: Feasibility with respect to engraftment, Incidence of graft-versus-host disease and 1 more. Planned start Dec 2010; status: withdrawn.
02
Drugs
innate donor lymphocyte infusioncyclosporinezoledronic acid
03
Conditions
Acute Leukaemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON34123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34123.